91高清自产国产拍,无码免费A级毛片大全,日本欧美国产中文字幕,99re热视频这里只有精品视频首页

400-620-6333

提交您使用阿拉丁产品的研究文章，就得100元奖励！立即访问我们的提交页面.

语言

切换导航

我的购物车

搜索

语言

拉罗替尼

规格或纯度: 97%

CAS编号: 1223403-58-4
分子式: C₂₁H₂₂F₂N₆O₂
分子量: 428.4
EC号: 826-190-2
PubChem编号: 46188928

有货

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭

库存信息

关闭

货号 (SKU)	包装规格	是否现货	价格	数量
L172696-5mg	5mg	现货
L172696-10mg	10mg	现货
L172696-25mg	25mg	现货
L172696-50mg	50mg	现货
L172696-100mg	100mg	现货

查看相关系列

neurotrophic receptor tyrosine kinase 1 Inhibitor

Skip to the end of the images gallery

main product photo

Skip to the beginning of the images gallery

基本描述

规格或纯度	97%
英文名称	LarotrectinibFor
英文别名	Vitrakvi;LOXO-101;ARRY-470
储存温度	-20°C储存
运输条件	超低温冰袋运输
产品介绍	Larotrectinib (Vitrakvi, LOXO-101, ARRY-470) 是一种具有ATP竞争性的、口服给药的 tropomyosin-related kinase (TRK) family receptors 的高度选择性抑制剂。

名称和标识符

EC号	826-190-2
IUPAC Name	(3S)-N-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide
INCHI	InChI=1S/C21H22F2N6O2/c22-13-3-4-16(23)15(10-13)18-2-1-7-28(18)19-6-9-29-20(26-19)17(11-24-29)25-21(31)27-8-5-14(30)12-27/h3-4,6,9-11,14,18,30H,1-2,5,7-8,12H2,(H,25,31)/t14-,18+/m0/s1
InChi Key	NYNZQNWKBKUAII-KBXCAEBGSA-N
Canonical SMILES	C1CC(N(C1)C2=NC3=C(C=NN3C=C2)NC(=O)N4CCC(C4)O)C5=C(C=CC(=C5)F)F
关联CAS	1223403-58-4
PubChem CID	46188928
MeSH Entry Terms	(3S)-N-(5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide;ARRY-470;ARRY470;BAY-2757556;BAY2757556;larotrectinib;LOXO-101;LOXO101;N-(5-(2-(2,5-difluorophenyl)pyrrolidin-1-yl)pyrazolo(1,5-a)pyrimidin-
分子量	428.4

安全和危险性（GHS）

象形图	Harmful
信号词	Warning
危险声明	H302: Harmful if swallowed H317: May cause an allergic skin reaction
预防措施声明	P280

关联配体

Ligand ID	8909
名称	larotrectinib
别名	example 14 [US8865698 B2]
类别	Synthetic organic
学名	(3S)-N-[5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl]-3-hydroxypyrrolidine-1-carboxamide
生物活性评价	The sulfonamide class of antibacterial compounds are primarily bacteriostatic agents and have a broad spectrum of activity against both Gram-positive and Gram-negative species of bacteria (reviewed in ).
评价	Larotrectinib (LOXO-101) is an orally available, potent and selective inhibitor of the receptor tyrosine kinases of the TRK family . In these referenced patents, data is provided for inhibition of neurotrophic tyrosine kinase, receptor, type 1 (NTRK1, a.k.a. TrkA) .
临床描述	This research study is done to test the safety of the drug larotrectinib in adult cancer patients. The drug may be used to treat cancer with a change in a particular gene (NTRK1, NTRK2 or NTRK3), because it blocks the action of these genes in cancer cells. The study also investigates how the drug is absorbed and processed in the human body. This is the first study to test larotrectinib in humans with cancer, for whom no other effective therapy exists. This research study is done to test how well different types of cancer respond to the drug called larotrectinib. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3). Larotrectinib is a drug that blocks the actions of these NTRK genes in cancer cells and can therefore be used to treat cancer.
来源公司	Bayer Bayer

相关文档

质检报告COA

请输入批号:

SDS中文版 SDS英文版

质量技术规格说明书

产品问答

产品问答

登录提交问题

您提交该产品问题后,我们会在1-2个工作日内给您答复,您可以登录"我的账号",然后点击"我的产品问答"查看答案

参考文献

1. Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, Nathenson M, Doebele RC, Farago AF, Pappo AS et al.. (2018) Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.. N Engl J Med, 378 (8): (731-739). [PMID:29466156]
2. Scott LJ. (2019) Larotrectinib: First Global Approval.. Drugs, 79 (2): (201-206). [PMID:30635837]

上海阿拉丁生化科技股份有限公司

销售条款及条件 ? ? ? ? 隐私政策

? 2016 ALADDIN-E.COM . 版权所有,未经授权禁止拷贝本站资料,如有违反,将追究法律责任

沪公网安备 31012002004058号沪ICP备09093490号-2

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用。

危险品化学品经营许可证（带存储）

营业执照(三证合一)